Company · London
The British drugmaker's most concrete UK quantum computing work is an NQCC proof of concept led by Capgemini UK, which used Hamiltonian simulation to build a "quantum fingerprint" for predicting how reactive the warheads of targeted covalent drugs are, tested so far mostly on simulators. GSK was also a project partner in the Oxford-led Quantum Computing and Simulation Hub (2019 to 2024). Its public quantum messaging has since shifted to defence: chief information security officer Michael Elmore argued in May 2026 that crypto-agility is needed now because encrypted data is already being harvested for later decryption.
GSK, based in London, is a company whose work covers quantum pharma, optimisation and machine learning; it was founded in 2020. It appears as a partner in QCS.
Sources: NQCC: Data-driven reactivity prediction using computed quantum features for drug discovery · arXiv: Data-driven reactivity prediction of targeted covalent inhibitors using computed quantum features · Gateway to Research: EP/T001062/1, Quantum Computing and Simulation Hub · GSK: Post-quantum cryptography · EIN Presswire: GSK global CISO warns the quantum threat to enterprise security is already here (May 2026)
QCS
The phase 2 national hub for quantum computing and simulation, led by the University of Oxford. It ran from 2019 to 2024.
Role: Partner
Funding: £27.3m
Themes: Computing, Software and algorithms
Research, commercial and investment relationships, by year. Partners with a profile here are linked.
Capgemini Research 2023
NQCC Research 2023
D-Wave Research 2021
Chosen by shared specialisms, then location and type.
Company · London · 2 shared specialisms
Company · London · 2 shared specialisms
Enterprise adopter · London · 2 shared specialisms
Investor · London · 2 shared specialisms
Company data from Entangled Future. Last checked 2 October 2026.
Logos and names are trademarks of their respective owners, used to identify them. No endorsement implied.
